Compare Cassava Sciences Inc (FLNA) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs IAC/Interactivecorp — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while IAC/Interactivecorp trades at $40.88 (market cap $3.05B). The key difference: IAC/Interactivecorp is far larger — about 77.4× Cassava Sciences Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and IAC/Interactivecorp for 79 Days on average.
| FLNA | PPLI | |
|---|---|---|
Market Cap | $39.40M | $3.05B |
Volume | 759,018 | 931,019 |
Sector | Health | Media |
52-Week High | $4.64 | $47.62 |
52-Week Low | $0.68 | $31.52 |
Typical Hold Time | 37 Days | 79 Days |
Enterprise Value | -$43.28M | $3.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.
While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.
PPLI trades at $40.89, up 0.74% with strong analyst support (71% buy ratings) amid MGM acquisition speculation. The stock shows bullish technical momentum with recent earnings volatility - missing Q4 2025 and Q1 2026 but beating Q2 2026 expectations. Revenue declined to $2.39B in 2025 while maintaining healthy gross margins of 66.35%. The company's valuation appears attractive with P/E of 6.92 and P/B of 0.6, though negative cash flow of -$820M in 2025 raises concerns.
The outlook remains positive given potential MGM bid and improving 2026 profit projections (14.12% margin). Key risks include volatile earnings, declining revenue trends, and negative cash flow. With strong institutional support and takeover speculation, the stock offers upside potential but requires monitoring of operational turnaround and acquisition developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
